UTAH MEDICAL PRODUCTS INC (UTMD) Fundamental Analysis & Valuation

NASDAQ:UTMD • US9174881089

Current stock price

61.54 USD
-1.06 (-1.69%)
At close:
64.63 USD
+3.09 (+5.02%)
After Hours:

This UTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. UTMD Profitability Analysis

1.1 Basic Checks

  • In the past year UTMD was profitable.
  • UTMD had a positive operating cash flow in the past year.
  • UTMD had positive earnings in each of the past 5 years.
  • Each year in the past 5 years UTMD had a positive operating cash flow.
UTMD Yearly Net Income VS EBIT VS OCF VS FCFUTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.53%, UTMD belongs to the top of the industry, outperforming 89.95% of the companies in the same industry.
  • UTMD's Return On Equity of 9.83% is amongst the best of the industry. UTMD outperforms 82.54% of its industry peers.
  • UTMD has a better Return On Invested Capital (8.26%) than 83.60% of its industry peers.
  • UTMD had an Average Return On Invested Capital over the past 3 years of 12.32%. This is above the industry average of 9.31%.
  • The last Return On Invested Capital (8.26%) for UTMD is well below the 3 year average (12.32%), which needs to be investigated, but indicates that UTMD had better years and this may not be a problem.
Industry RankSector Rank
ROA 9.53%
ROE 9.83%
ROIC 8.26%
ROA(3y)12.3%
ROA(5y)11.87%
ROE(3y)13.06%
ROE(5y)12.7%
ROIC(3y)12.32%
ROIC(5y)12.29%
UTMD Yearly ROA, ROE, ROICUTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

  • The Profit Margin of UTMD (30.08%) is better than 98.41% of its industry peers.
  • UTMD's Profit Margin has improved in the last couple of years.
  • UTMD's Operating Margin of 30.78% is amongst the best of the industry. UTMD outperforms 97.88% of its industry peers.
  • In the last couple of years the Operating Margin of UTMD has remained more or less at the same level.
  • The Gross Margin of UTMD (57.10%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of UTMD has remained more or less at the same level.
Industry RankSector Rank
OM 30.78%
PM (TTM) 30.08%
GM 57.1%
OM growth 3Y-0.06%
OM growth 5Y0.46%
PM growth 3Y4%
PM growth 5Y1.55%
GM growth 3Y-2.17%
GM growth 5Y-1.24%
UTMD Yearly Profit, Operating, Gross MarginsUTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

10

2. UTMD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTMD is still creating some value.
  • Compared to 1 year ago, UTMD has less shares outstanding
  • UTMD has less shares outstanding than it did 5 years ago.
  • UTMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UTMD Yearly Shares OutstandingUTMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
UTMD Yearly Total Debt VS Total AssetsUTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • UTMD has an Altman-Z score of 35.21. This indicates that UTMD is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 35.21, UTMD belongs to the top of the industry, outperforming 97.35% of the companies in the same industry.
  • There is no outstanding debt for UTMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 35.21
ROIC/WACC0.77
WACC10.7%
UTMD Yearly LT Debt VS Equity VS FCFUTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • UTMD has a Current Ratio of 32.06. This indicates that UTMD is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 32.06, UTMD belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
  • UTMD has a Quick Ratio of 29.36. This indicates that UTMD is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 29.36, UTMD belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 32.06
Quick Ratio 29.36
UTMD Yearly Current Assets VS Current LiabilitesUTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. UTMD Growth Analysis

3.1 Past

  • UTMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.30%.
  • The Earnings Per Share has been growing slightly by 0.16% on average over the past years.
  • The Revenue for UTMD has decreased by -12.35% in the past year. This is quite bad
  • The Revenue has been decreasing by -2.70% on average over the past years.
EPS 1Y (TTM)-17.3%
EPS 3Y-0.66%
EPS 5Y0.16%
EPS Q2Q%-19.91%
Revenue 1Y (TTM)-12.35%
Revenue growth 3Y-5.87%
Revenue growth 5Y-2.7%
Sales Q2Q%-1.93%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UTMD Yearly Revenue VS EstimatesUTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

Find the best growth stocksShow best growing peers

5

4. UTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • UTMD is valuated rather expensively with a Price/Earnings ratio of 17.38.
  • Based on the Price/Earnings ratio, UTMD is valued cheaply inside the industry as 82.54% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 24.88. UTMD is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.38
Fwd PE N/A
UTMD Price Earnings VS Forward Price EarningsUTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 95.24% of the companies in the same industry are more expensive than UTMD, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, UTMD is valued cheaper than 96.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.14
EV/EBITDA 7.79
UTMD Per share dataUTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • UTMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)111.98
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. UTMD Dividend Analysis

5.1 Amount

  • UTMD has a Yearly Dividend Yield of 1.94%.
  • Compared to an average industry Dividend Yield of 0.24, UTMD pays a better dividend. On top of this UTMD pays more dividend than 95.24% of the companies listed in the same industry.
  • UTMD's Dividend Yield is comparable with the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.94%

5.2 History

  • The dividend of UTMD has a limited annual growth rate of 1.95%.
  • UTMD has paid a dividend for at least 10 years, which is a reliable track record.
  • UTMD has decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.95%
Div Incr Years2
Div Non Decr Years2
UTMD Yearly Dividends per shareUTMD Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

5.3 Sustainability

  • 34.80% of the earnings are spent on dividend by UTMD. This is a low number and sustainable payout ratio.
  • UTMD's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP34.8%
EPS Next 2YN/A
EPS Next 3YN/A
UTMD Yearly Income VS Free CF VS DividendUTMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M
UTMD Dividend Payout.UTMD Dividend Payout, showing the Payout Ratio.UTMD Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UTMD Fundamentals: All Metrics, Ratios and Statistics

UTAH MEDICAL PRODUCTS INC

NASDAQ:UTMD (3/27/2026, 8:00:01 PM)

After market: 64.63 +3.09 (+5.02%)

61.54

-1.06 (-1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-03
Earnings (Next)04-27
Inst Owners69.69%
Inst Owner Change-4.02%
Ins Owners7.18%
Ins Owner Change0%
Market Cap196.31M
Revenue(TTM)38.63M
Net Income(TTM)11.62M
Analysts0
Price TargetN/A
Short Float %3.74%
Short Ratio7.47
Dividend
Industry RankSector Rank
Dividend Yield 1.94%
Yearly Dividend1.22
Dividend Growth(5Y)1.95%
DP34.8%
Div Incr Years2
Div Non Decr Years2
Ex-Date03-17
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 17.38
Fwd PE N/A
P/S 5.08
P/FCF 14.14
P/OCF 13.87
P/B 1.66
P/tB 1.91
EV/EBITDA 7.79
EPS(TTM)3.54
EY5.75%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.35
FCFY7.07%
OCF(TTM)4.44
OCFY7.21%
SpS12.11
BVpS37.07
TBVpS32.23
PEG (NY)N/A
PEG (5Y)111.98
Graham Number54.34
Profitability
Industry RankSector Rank
ROA 9.53%
ROE 9.83%
ROCE 9.99%
ROIC 8.26%
ROICexc 28.34%
ROICexgc 51.06%
OM 30.78%
PM (TTM) 30.08%
GM 57.1%
FCFM 35.93%
ROA(3y)12.3%
ROA(5y)11.87%
ROE(3y)13.06%
ROE(5y)12.7%
ROIC(3y)12.32%
ROIC(5y)12.29%
ROICexc(3y)38.7%
ROICexc(5y)33.39%
ROICexgc(3y)78.49%
ROICexgc(5y)75.65%
ROCE(3y)14.9%
ROCE(5y)14.86%
ROICexgc growth 3Y-5.7%
ROICexgc growth 5Y-2.21%
ROICexc growth 3Y5.77%
ROICexc growth 5Y9.65%
OM growth 3Y-0.06%
OM growth 5Y0.46%
PM growth 3Y4%
PM growth 5Y1.55%
GM growth 3Y-2.17%
GM growth 5Y-1.24%
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 9.27%
Cap/Sales 0.7%
Interest Coverage 250
Cash Conversion 95.53%
Profit Quality 119.44%
Current Ratio 32.06
Quick Ratio 29.36
Altman-Z 35.21
F-Score6
WACC10.7%
ROIC/WACC0.77
Cap/Depr(3y)10.06%
Cap/Depr(5y)9.94%
Cap/Sales(3y)1.14%
Cap/Sales(5y)1.32%
Profit Quality(3y)119.58%
Profit Quality(5y)135.38%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.3%
EPS 3Y-0.66%
EPS 5Y0.16%
EPS Q2Q%-19.91%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.35%
Revenue growth 3Y-5.87%
Revenue growth 5Y-2.7%
Sales Q2Q%-1.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.61%
EBIT growth 3Y-5.93%
EBIT growth 5Y-2.25%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.02%
FCF growth 3Y-10.92%
FCF growth 5YN/A
OCF growth 1Y-37.46%
OCF growth 3Y-11.23%
OCF growth 5Y-2.76%

UTAH MEDICAL PRODUCTS INC / UTMD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of UTAH MEDICAL PRODUCTS INC (UTMD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to UTMD.


What is the valuation status of UTAH MEDICAL PRODUCTS INC (UTMD) stock?

ChartMill assigns a valuation rating of 5 / 10 to UTAH MEDICAL PRODUCTS INC (UTMD). This can be considered as Fairly Valued.


How profitable is UTAH MEDICAL PRODUCTS INC (UTMD) stock?

UTAH MEDICAL PRODUCTS INC (UTMD) has a profitability rating of 8 / 10.


What are the PE and PB ratios of UTAH MEDICAL PRODUCTS INC (UTMD) stock?

The Price/Earnings (PE) ratio for UTAH MEDICAL PRODUCTS INC (UTMD) is 17.38 and the Price/Book (PB) ratio is 1.66.


What is the financial health of UTAH MEDICAL PRODUCTS INC (UTMD) stock?

The financial health rating of UTAH MEDICAL PRODUCTS INC (UTMD) is 10 / 10.